|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Translational Investigations |
1 Professor of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave., A-808, San Francisco, CA 94143–0350, USA
2 Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA
3 Department of Nursing, University of Virginia, Charlottesville, VA
* To whom correspondence should be addressed. E-mail: changs{at}neurosurg.ucsf.edu.
| Abstract |
|---|
Quality of life is an important area of clinical neuro-oncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. This review of quality-of-life studies done in the brain tumor population aims to summarize what is currently known about quality of life in patients with both low-grade and high-grade tumors and suggest how we may use this knowledge to direct future research. To date reports on quality of life have been primarily qualitative and focused on specific symptoms such as fatigue, sleep disorders, and cognitive dysfunction, as well as some symptom clusters. However, the increasing interest in exploring quality of life as a primary endpoint for cancer therapy has established a need for prospective, controlled studies to assess baseline and serial quality-of-life parameters in brain-tumor patients in order to plan and evaluate appropriate and timely intervention for their symptoms.
Key Words: brain tumor, clinical trial endpoints, quality of life, survivorship, symptom management
|
|